CRISPR Therapeutics AG (CRSP)
55.61
-1.47
(-2.58%)
USD |
NASDAQ |
May 07, 14:16
CRISPR Therapeutics Free Cash Flow: -272.34M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -272.34M |
| September 30, 2023 | -295.05M |
| June 30, 2023 | -363.31M |
| March 31, 2023 | -376.60M |
| December 31, 2022 | -532.93M |
| September 30, 2022 | -508.63M |
| June 30, 2022 | -515.77M |
| March 31, 2022 | 414.36M |
| December 31, 2021 | 457.27M |
| September 30, 2021 | 465.04M |
| June 30, 2021 | 502.19M |
| March 31, 2021 | -309.24M |
| December 31, 2020 | -256.72M |
| September 30, 2020 | -166.85M |
| June 30, 2020 | 45.33M |
| Date | Value |
|---|---|
| March 31, 2020 | 39.66M |
| December 31, 2019 | 49.99M |
| September 30, 2019 | 18.20M |
| June 30, 2019 | -133.42M |
| March 31, 2019 | -120.60M |
| December 31, 2018 | -99.01M |
| September 30, 2018 | -84.69M |
| June 30, 2018 | -82.89M |
| March 31, 2018 | -74.45M |
| December 31, 2017 | -77.91M |
| September 30, 2017 | -80.05M |
| June 30, 2017 | -74.98M |
| March 31, 2017 | -72.33M |
| December 31, 2016 | -55.88M |
Free Cash Flow Range, Past 5 Years
-532.93M
Minimum
Dec 2022
502.19M
Maximum
Jun 2021
-91.52M
Average
-166.85M
Median
Sep 2020
Free Cash Flow Benchmarks
| Vertex Pharmaceuticals Inc | 3.279B |
| Intellia Therapeutics Inc | -408.07M |
| Novartis AG | 10.25B |
| AC Immune SA | -68.17M |
| Addex Therapeutics Ltd | -8.908M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -96.07M |
| Cash from Investing (Quarterly) | -81.45M |
| Cash from Financing (Quarterly) | 38.94M |
| Free Cash Flow Per Share (Quarterly) | -1.215 |
| Free Cash Flow to Equity (Quarterly) | -96.81M |
| Free Cash Flow to Firm (Quarterly) | -96.81M |
| Free Cash Flow Yield | -6.18% |